Abstract:Introduction There is still lack of specific biomarkers in predicting the radiosensitivity of non-small cell lung cancer (NSCLC) patients in clinic. Previous studies have shown that the EGFR gene status may correlate with radiosensitivity of NSCLC. However, the underlying mechanisms remain unknown. The aim of this study was to further investigate the correlation between EGFR mutation status and the NSCLC cell radiosensitivity and to explore the possible cellular mechanism. Methods Eight NSCLC cell lines with different EGFR gene status were irradiated by linear accelerator, and the radiosensitivity between the cell lines was compared by cell colony formation assay and cell proliferation assay. Cell cycle and apoptosis were analysed by flow cytometry. Radiosensitivity-related protein expression was detected by Western blotting. Results In the present study, we found that NSCLC cell lines with the epidermal growth factor receptor (EGFR) gene mutations were more sensitive to X-ray irradiation than those with wild-type EGFR (P<0.05). No difference in radiosensitivity was observed between NSCLC cells with EGFR exon19 deletion (Del 19) mutation and exon 21 point mutation at position 858 (L858R) with or without T790M mutation (P<0.05), as well as between NSCLC cells with EGFR mutation and those with acquired EGFR-tyrosine kinase inhibitors (TKIs) resistance. Mechanistically, EGFR mutations promoted NSCLC cell apoptosis in response to X-ray irradiation through the upregulation of proapoptotic protein Bax and downregulation of anti-apoptotic proteins such as Bcl-2 and DNA-dependent protein kinase catalytic subunit. In addition, phosphorylated histone (γ-H2AX) foci assay showed that EGFR mutations sustained irradiation-induced DNA damage. Conclusion Taken together, our study demonstrates that EGFR mutations are closely associated with the increased sensitivity of NSCLC cell lines to X-ray irradiation and that EGFR mutation status is a potentially useful indicator to evaluate the effectiveness of radiotherapy in the treatment of NSCLC.

EGFR and Radiosensitization of Tumor Cells

EGFR inhibitors and radiosensitivity of tumor cells

Epidermal Growth Factor Receptor Gene Mutations in Non-Small-cell Lung Cancer Cells Are Associated with Increased Radiosensitivity in Vitro

Nuclear EGFR:a Potential Target for Radiosensitizer

Role of Epidermal Growth Factor Receptor in Tumor Radiotherapy

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Epidermal Growth Factor Receptor Family Tyrosine Kinase and Cancer Therapy

EGFR-mediated DSB repair pathway in radiosensitization of rectal cancer

Platelet Derived Growth Factor and Its Receptor and the Radiation Resistance of Tumor Cells

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

EGFR-mediated Autophagy in Tumourigenesis and Therapeutic Resistance

Adaptive EGF Expression Sensitizes Pancreatic Cancer Cells to Ionizing Radiation Through Activation of the Cyclin D1/P53/PARP Pathway

Progress of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors in the Cancer Therapy

Combining radiotherapy with EGFR inhibitor for NSCLC:principle and present status

Role of nuclear epidermal growth factor receptor in tumorigenesis and resistant to treatment

The Regulation Effect of EGFR Signaling Pathway on PD-L1 Expression on Esophageal Squamous Cell Carcinoma Cell Lines.

Role of Epidermal Growth Factor Receptor in DNA Damage Repair

Progression in the mechanisms of EGFR inhibitors combined with radiotherapy

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Effect of EGFR Mutation on Radiation-Induced DNA Repair in Pulmonary Adenocarcinoma Cells

Epigenetic regulation of TGF-β pathway and its role in radiation response